Towards personalised dosimetry in patients with liver malignancy treated with 90Y-SIRT using in vivo-driven radiobiological parameters

EJNMMI Physics

Table 2 A list of estimated critical dose rate, \(R_{{{\text{critic}}}}\) and time, \(T_{{{\text{critic}}}}\)

Cancer type	\(R_{{{\text{critic}}}}\)(Gy/days)	\(R_{{{\text{critic}}\left( k \right)}}\)(Gy/days)	\(R_{0}\)(Gy/days)	\(T_{{{\text{critic}}}}\)(days)
Breast	0.620	3.32	12.3	12
PNET	0.465	3.45	13.1	13
Adrenocortical carcinoma	1.0	16.3	13.5	10
CRC	0.814	5.24	32.8	14
Cholangiocarcinoma	0.231	1.13	7.28	13
CRC	1.0	56.1	8.62	8
CRC	0.481	3.01	11.0	12
Rectal adenocarcinoma	0.012	0.13	3.18	22
Cholangiocarcinoma	0.02	0.14	8.82	23
CRC	0.777	6.76	8.59	9
Cholangiocarcinoma	11.7	693	70.5	7
Cholangiocarcinoma	0.041	0.60	10.2	21
Sigmoid adenocarcinoma	0.015	0.13	13.0	26
Breast	0.048	0.16	11.8	21
Prostate	0.028	0.12	8.65	22
mCRC	0.238	0.46	7.65	13
PNET	5.00 × 10⁻³	0.01	11.0	30
PDAC	0.013	0.05	2.29	20
SBNET	0.003	0.02	59.8	38
Mesothelioma	0.442	1.76	15.5	14
PNET	0.028	0.12	25.4	26
HCC	3.070	26.5	20.9	7
Oesophageal	0.069	0.30	4.58	16
SBNET	0.362	2.36	12.9	14
NEC	0.284	22.4	4.44	11

\(R_{{{\text{critic}}}}\), critical dose rate; \(R_{{{\text{critic}}\left( k \right)}}\), critical dose rate considering the \(T_{{\text{k}}}\); \(R_{0}\), initial dose rate; \(T_{{{\text{critic}}}}\), critical time.